6. What were the four most common psychological symptoms reported by this sample
ID: 3200067 • Letter: 6
Question
6. What were the four most common psychological symptoms reported by this sample of patients with COPD? What percentage of these subjects experienced these symptoms? Was there a signi?cant difference between the moderate and severe air?ow limitation groups for psychological symptoms? 9. Was the percentage of COPD patients with moderate and severe air?ow limitation using short-acting ? 2 -agonists what you expected? Provide a rationale with documentation for your answer. 10. Are these ?ndings ready for use in practice? Provide a rationale for your answer. 6. What were the four most common psychological symptoms reported by this sample of patients with COPD? What percentage of these subjects experienced these symptoms? Was there a signi?cant difference between the moderate and severe air?ow limitation groups for psychological symptoms? 9. Was the percentage of COPD patients with moderate and severe air?ow limitation using short-acting ? 2 -agonists what you expected? Provide a rationale with documentation for your answer. 10. Are these ?ndings ready for use in practice? Provide a rationale for your answer. TABLE 1 BACKGROUND CHARACTERISTICS AND USE OF MEDICATION FOR PATIENTS WITH STABLE CHRONICOBSTRUCTIVE LUNG DISEASE CLASSIFIED IN PATIENTS WITH MODERATE AND SEVERE AIRFLow LIMITATION Moderate Severe 42 49 p Value Sex, n (9%) 0.607 Women 19 (45) 29 (59) Men 23 (55) 20 (41) Age (yrs), mean (SD) 66.5 (8.6) 67.9 (6.8) 0.396 Married/cohabitant n 29 (69) 34 (71) 0.854 Employed, n (96) 0.754 Smoking, n 0.789 Smoking 13 (31) 12 (24) Former smokers 28 (67) 35 (71) Never smokers 1 (2) 2 (4) Pack years smoking, mean (SD) 29.1 (13.5) 34.0 (9.5) BMI (kg/m2), mean (SD) 27.2 (5.2) 26.5 (6.1) 0.555 FEV1% of predicted, mean (SD) 61.6 (8.4) 42.2 (5.8)Explanation / Answer
(9) In this case study, 31% of the COPD patients with moderate airow limitation and 65% of the COPD patients with severe airow limitation were treated using short-acting 2 -agonists.
Mean percent = (31 + 65) / 2 =48%
The use of short-acting 2 -agonists is more common for the COPD patients with severe airow limitation.
Whereas the use of short-acting 2 -agonists is rare for the COPD patients with moderate airow limitation.
So we might not expect that a large percent of COPD patients in this case study are using short-acting 2 -agonists.
(6) Need more information. Please provide the additional information apart from the table, as was given in the question.
(10) Not all the findings are ready for use in practice.
For eg. the use of Inhaled glucocorticosteroids is very common among both the groups, the COPD patients with moderate airow limitation and severe airow limitation
Also the use of Anticholinergic is very common among both the groups of COPD patients.
However we see that the moderate airow limitation and severe airow limitation groups are significantly different with respect to the use of Inhaled glucocorticosteroids (as p-value = 0.025 < 0.05)
Whereas the moderate airow limitation and severe airow limitation groups are not significantly different with respect to the use of Anticholinergic (as p-value = 0.245 > 0.05)
So all the findings are not ready for use in practice.
Related Questions
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.